OncoMatch

OncoMatch/Clinical Trials/NCT05787587

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Is NCT05787587 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including IDE-161 and Pembrolizumab for advanced or metastatic solid tumors.

Phase 1RecruitingIDEAYA BiosciencesNCT05787587Data as of May 2026

Treatment: IDE-161 · Pembrolizumab — The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Breast Carcinoma

Ovarian Cancer

Prostate Cancer

Endometrial Cancer

Colorectal Cancer

Small Cell Lung Cancer

Non-Small Cell Lung Carcinoma

Biomarker criteria

Required: BRCA1 genetic alteration conferring HRD

documented evidence of BRCA1/2 and/or genetic alterations conferring homologous recombination deficiency (HRD)

Required: BRCA2 genetic alteration conferring HRD

documented evidence of BRCA1/2 and/or genetic alterations conferring homologous recombination deficiency (HRD)

Required: ATM genetic alteration conferring HRD

documented evidence of BRCA1/2 and/or genetic alterations conferring homologous recombination deficiency (HRD) (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, NBN, FANCA)

Required: BARD1 genetic alteration conferring HRD

documented evidence of BRCA1/2 and/or genetic alterations conferring homologous recombination deficiency (HRD) (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, NBN, FANCA)

Required: BRIP1 genetic alteration conferring HRD

documented evidence of BRCA1/2 and/or genetic alterations conferring homologous recombination deficiency (HRD) (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, NBN, FANCA)

Required: CDK12 genetic alteration conferring HRD

documented evidence of BRCA1/2 and/or genetic alterations conferring homologous recombination deficiency (HRD) (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, NBN, FANCA)

Required: CHEK1 genetic alteration conferring HRD

documented evidence of BRCA1/2 and/or genetic alterations conferring homologous recombination deficiency (HRD) (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, NBN, FANCA)

Required: CHEK2 genetic alteration conferring HRD

documented evidence of BRCA1/2 and/or genetic alterations conferring homologous recombination deficiency (HRD) (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, NBN, FANCA)

Required: FANCL genetic alteration conferring HRD

documented evidence of BRCA1/2 and/or genetic alterations conferring homologous recombination deficiency (HRD) (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, NBN, FANCA)

Required: PALB2 genetic alteration conferring HRD

documented evidence of BRCA1/2 and/or genetic alterations conferring homologous recombination deficiency (HRD) (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, NBN, FANCA)

Required: PPP2R2A genetic alteration conferring HRD

documented evidence of BRCA1/2 and/or genetic alterations conferring homologous recombination deficiency (HRD) (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, NBN, FANCA)

Required: RAD51B genetic alteration conferring HRD

documented evidence of BRCA1/2 and/or genetic alterations conferring homologous recombination deficiency (HRD) (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, NBN, FANCA)

Required: RAD51C genetic alteration conferring HRD

documented evidence of BRCA1/2 and/or genetic alterations conferring homologous recombination deficiency (HRD) (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, NBN, FANCA)

Required: RAD51D genetic alteration conferring HRD

documented evidence of BRCA1/2 and/or genetic alterations conferring homologous recombination deficiency (HRD) (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, NBN, FANCA)

Required: RAD54L genetic alteration conferring HRD

documented evidence of BRCA1/2 and/or genetic alterations conferring homologous recombination deficiency (HRD) (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, NBN, FANCA)

Required: NBN genetic alteration conferring HRD

documented evidence of BRCA1/2 and/or genetic alterations conferring homologous recombination deficiency (HRD) (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, NBN, FANCA)

Required: FANCA genetic alteration conferring HRD

documented evidence of BRCA1/2 and/or genetic alterations conferring homologous recombination deficiency (HRD) (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, NBN, FANCA)

Disease stage

Metastatic disease required

Advanced or metastatic

Prior therapy

Min 1 prior line

Must have received: appropriate standard of care therapy — advanced or metastatic

progressed on at least one prior line of therapy in the advanced or metastatic setting that is considered an appropriate standard of care, or for which the participant has documented intolerance

Must have received: anti-PD-1/L1 monoclonal antibody

Must have progressed on treatment with an anti-PD-1/L1 monoclonal antibody (MAB)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • HonorHealth Research Institute · Phoenix, Arizona
  • The Angeles Clinic · Los Angeles, California
  • Hoag Memorial Hospital · Newport Beach, California
  • California Pacific Medical Center · San Francisco, California
  • Sarah Cannon Research Institute · Denver, Colorado

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify